I care less about what the share price movement will be in the...

I care less about what the share price movement will be in the short term, rather I will focus on what the data and learnings are so far in the CLTX phase 1 trial. The share price may go down, remain unchanged or go up in the short term, there are too many factors to consider that could impact it.. and focusing and relying on 'validation' from the market, is in my view, a red herring / distraction on the bigger picture.

If this trial is successful the returns will be astronomical. The only thing that will determine if this will become reality is clinical data. Not the share price.

In terms of big pharma having interest in CHM, I personally don't think that is good for CHM at such an early stage. And to be honest, big pharma are not typically interested in early stage assets which carry the highest risk of failure. Big pharma will pay 'big dollars' for de-risked assets, and I think Jen's comment reflects the fact that once we get final phase 1 results, assuming the data is positive enough, the phase 2 trial would be an approval trial, which is where big pharma would be interested to step in and partner or acquire said asset.